A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Vonoprazan (Primary) ; Lansoprazole
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2013 New trial record
    • 21 May 2013 Results presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top